Miguet Céline, Jauffret Camille, Zemmour Christophe, Boher Jean-Marie, Sabiani Laura, Houvenaeghel Gilles, Blache Guillaume, Brun Clément, Lambaudie Eric
Department of Surgical Oncology, Institute Paoli-Calmettes, 13009 Marseille, France.
Biostatistics and Methodology Unit, Department of Clinical Research and Investigation, Institute Paoli-Calmettes, Aix Marseille University, INSERM, IRD, SESSTIM, 13009 Marseille, France.
Cancers (Basel). 2023 Jun 19;15(12):3244. doi: 10.3390/cancers15123244.
Endometrial cancer is the fifth most common cancer among French women and occurs most frequently in the over-70-year-old population. Recent years have seen a significant shift towards minimally invasive surgery and Enhanced Recovery After Surgery (ERAS) protocols in endometrial cancer management. However, the impact of ERAS on endometrial cancer has not been well-established. We conducted a prospective observational study in a comprehensive cancer center, comparing the outcomes between endometrial cancer patients who received care in an ERAS pathway (261) and those who did not (166) between 2006 and 2020. We performed univariate and multivariate analysis. Our primary objective was to evaluate the impact of ERAS on length of hospital stay (LOS), with the secondary objectives being the determination of the rates of early discharge, post-operative morbidity, and rehospitalization. We found that patients in the ERAS group had a significantly shorter length of stay, with an average of 3.18 days compared to 4.87 days for the non-ERAS group (estimated decrease -1.69, < 0.0001). This effect was particularly pronounced among patients over 70 years old (estimated decrease -2.06, < 0.0001). The patients in the ERAS group also had a higher chance of early discharge (47.5% vs. 14.5% in the non-ERAS group, < 0.0001), for which there was not a significant increase in post-operative complications. Our study suggests that ERAS protocols are beneficial for the management of endometrial cancer, particularly for older patients, and could lead to the development of ambulatory pathways.
子宫内膜癌是法国女性中第五大常见癌症,最常发生于70岁以上人群。近年来,子宫内膜癌的治疗显著转向微创手术和术后加速康复(ERAS)方案。然而,ERAS对子宫内膜癌的影响尚未明确。我们在一家综合癌症中心进行了一项前瞻性观察研究,比较了2006年至2020年间接受ERAS治疗的子宫内膜癌患者(261例)和未接受ERAS治疗的患者(166例)的治疗结果。我们进行了单因素和多因素分析。我们的主要目标是评估ERAS对住院时间(LOS)的影响,次要目标是确定早期出院率、术后发病率和再住院率。我们发现,ERAS组患者的住院时间明显缩短,平均为3.18天,而非ERAS组为4.87天(估计减少-1.69,<0.0001)。这种影响在70岁以上患者中尤为明显(估计减少-2.06,<0.0001)。ERAS组患者早期出院的可能性也更高(47.5% vs.非ERAS组的14.5%,<0.0001),术后并发症没有显著增加。我们的研究表明,ERAS方案对子宫内膜癌的治疗有益,尤其是对老年患者,并且可能导致门诊治疗路径的发展。